{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:15:28Z","timestamp":1773396928536,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a hematological malignancy with increasing incidence among adolescents and young adults (AYAs) aged 15 to 39\u00a0years. This trend presents unique challenges related to long-term treatment effects, fertility, and late-onset complications. Risk factors include obesity, diabetes, environmental exposures, and genetic predispositions, with a higher incidence observed in males and individuals of African-American descent. This study aims to analyze global trends in MM incidence and mortality among AYAs from 1990 to 2021 and project future trends through 2040.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed the age-specificincidence rate (IR), and death rate (DR) per 100,000 patient-years of AYA MM. Statistical modeling, including two sample t-test were done to estimate the standard deviations among each group, which is plugged into the denominator to compute the statistic. Auto-Regressive Integrated Moving Average (ARIMA) and Exponential Smoothing State Space (ETS) models were applied for projections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the global AYA MM incidence was 2536 cases (IR 0.09\/100,000 patient-years), and deaths totaled 1579 (DR 0.05\/100,000 patient-years). From 1990 to 2021, IR and DR increased (annual percentage change (APC) of 0.84 for IR and 0.60 for DR). Males exhibited higher rates and faster increases. High-middle SDI regions had the highest IR and DR, with Mauritius recording the highest national rates. High BMI contributed to 6.52% of MM-related deaths in 2021. Projections indicate rising IR and DR globally through 2040.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The increasing burden of AYA MM necessitates early detection, targeted treatments, and preventive measures addressing obesity and other modifiable risk factors. Reducing regional disparities through improved healthcare access is essential to mitigate the growing impact of MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-026-02142-3","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:37:42Z","timestamp":1771493862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple myeloma in adolescents and young adults(AYA): global epidemiological trends, risk factors, and future projections (1990\u20132040)"],"prefix":"10.1007","volume":"37","author":[{"given":"Rupayan","family":"Kundu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankush","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivedita","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niladri","family":"Kal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuhin Subhra","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"1","key":"2142_CR1","doi-asserted-by":"publisher","first-page":"20705","DOI":"10.1038\/s41598-023-47906-y","volume":"13","author":"SE Mousavi","year":"2023","unstructured":"Mousavi SE, Ilaghi M, Aslani A, Yekta Z, Nejadghaderi SA (2023) A population-based study on incidence trends of myeloma in the United States over 2000\u20132020. Sci Rep 13(1):20705","journal-title":"Sci Rep"},{"issue":"5","key":"2142_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al (2022) Diagnosis and Management of Multiple Myeloma. JAMA 327(5):464","journal-title":"JAMA"},{"issue":"1","key":"2142_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K et al (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606","journal-title":"BMC Cancer"},{"issue":"7","key":"2142_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1055-9965.EPI-07-0143","volume":"16","author":"BM Birmann","year":"2007","unstructured":"Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA (2007) Body Mass Index, Physical Activity, and Risk of Multiple Myeloma. Cancer Epidemiol Biomark Prev 16(7):1474\u20131478","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"7","key":"2142_CR5","first-page":"931","volume":"17","author":"M Gebregziabher","year":"2006","unstructured":"Gebregziabher M, Bernstein L, Wang Y, Cozen W (2006) Risk patterns of multiple myeloma in Los Angeles County, 1972\u20131999 (United States). Cancer Causes Control 17(7):931\u2013938","journal-title":"Cancer Causes Control"},{"issue":"11","key":"2142_CR6","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/ijc.22968","volume":"121","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Wolk A (2007) Body mass index and risk of multiple myeloma: A meta-analysis. Int J Cancer 121(11):2512\u20132516","journal-title":"Int J Cancer"},{"issue":"11","key":"2142_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1158\/1055-9965.EPI-19-0389","volume":"28","author":"T Ugai","year":"2019","unstructured":"Ugai T, Ito H, Oze I, Saito E, Rahman MS, Boffetta P et al (2019) Association of BMI, Smoking, and Alcohol with Multiple Myeloma Mortality in Asians: A Pooled Analysis of More than 800,000 Participants in the Asia Cohort Consortium. Cancer Epidemiol Biomark Prev 28(11):1861\u20131867","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2142_CR8","first-page":"305","volume":"7","author":"PP Soe","year":"2023","unstructured":"Soe PP, Win S, Hein M, Aung KT, Nyein MM, Robert A, Coutelier JP (2023) Impact of Environmental Factors on the Risk of Multiple Myeloma, a Case-Control Study in Myanmar. J Commun Med Public Health 7:305\u20131","journal-title":"J Commun Med Public Health"},{"issue":"2","key":"2142_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.21306","volume":"118","author":"A Nieters","year":"2006","unstructured":"Nieters A, Deeg E, Becker N (2006) Tobacco and alcohol consumption and risk of lymphoma: Results of apopulation-based case-control study in Germany. Int J Cancer 118(2):422\u2013430","journal-title":"Int J Cancer"},{"issue":"2","key":"2142_CR10","doi-asserted-by":"publisher","DOI":"10.34172\/npj.2023.10604","volume":"12","author":"A Rastegar-Kashkouli","year":"2023","unstructured":"Rastegar-Kashkouli A, Jafari M, Karami S, Yousefi P, Taravati AM, Khavaran A et al (2023) Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction. J Nephropharmacol 12(2):e10604","journal-title":"J Nephropharmacol"},{"issue":"18","key":"2142_CR11","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.3390\/jcm10184179","volume":"10","author":"R Georgakopoulou","year":"2021","unstructured":"Georgakopoulou R, Fiste O, Sergentanis TN, Andrikopoulou A, Zagouri F, Gavriatopoulou M et al (2021) Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. J Clin Med 10(18):4179","journal-title":"J Clin Med"},{"issue":"10062","key":"2142_CR12","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","volume":"388","author":"GA Stevens","year":"2016","unstructured":"Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M et al (2016) Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet 388(10062):e19-23","journal-title":"Lancet"},{"issue":"10440","key":"2142_CR13","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C et al (2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 403(10440):2100\u20132132","journal-title":"The Lancet"},{"issue":"10440","key":"2142_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2024","unstructured":"Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H et al (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 403(10440):2133\u20132161","journal-title":"The Lancet"},{"key":"2142_CR15","unstructured":"Team RR (2010) A language and environment for statistical computing."},{"issue":"9","key":"2142_CR16","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W et al (2022) The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 9(9):e670\u2013e677","journal-title":"Lancet Haematol"},{"issue":"4","key":"2142_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12185-020-02996-6","volume":"112","author":"A Nakaya","year":"2020","unstructured":"Nakaya A, Kohara T, Shibayama H, Onda Y, Kanda J, Kaneko H et al (2020) Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. Int J Hematol 112(4):435\u2013438","journal-title":"Int J Hematol"},{"issue":"14","key":"2142_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al (2017) Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 376(14):1311\u20131320","journal-title":"N Engl J Med"},{"issue":"6","key":"2142_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","volume":"7","author":"O Landgren","year":"2021","unstructured":"Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H et al (2021) Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncol 7(6):862","journal-title":"JAMA Oncol"},{"issue":"6","key":"2142_CR20","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/curroncol30060396","volume":"30","author":"M Tanguay","year":"2023","unstructured":"Tanguay M, Dagenais C, LeBlanc R, Ahmad I, Claveau JS, Roy J (2023) Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes. Curr Oncol 30(6):5214\u20135226","journal-title":"Curr Oncol"},{"issue":"3","key":"2142_CR21","first-page":"645","volume":"19","author":"A Waszczuk-Gajda","year":"2020","unstructured":"Waszczuk-Gajda A, Szafraniec-Bury\u0142o S, Kraj L, Skwierawska K, Aleksandrowicz K, Basak GW, Brzozowska M, Wierzba W, J\u0119drzejczak WW, \u015aliwczy\u0144ski A (2020) Epidemiology of multiple myeloma in Poland in the years 2008\u20132017. Arch Med Sci AMS 19(3):645","journal-title":"Arch Med Sci AMS"},{"issue":"2","key":"2142_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12185-025-03972-8","volume":"122","author":"K Kim","year":"2025","unstructured":"Kim K, Verburgh E, Mitina T, Chen W, Yeh SP, Schutz N et al (2025) Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study. Int J Hematol 122(2):231\u2013246","journal-title":"Int J Hematol"},{"issue":"10272","key":"2142_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410\u2013427","journal-title":"Lancet"},{"issue":"9","key":"2142_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP et al (2018) Global Burden of Multiple Myeloma. JAMA Oncol 4(9):1221","journal-title":"JAMA Oncol"},{"issue":"1","key":"2142_CR25","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1038\/s41467-023-41223-8","volume":"14","author":"JH Huber","year":"2023","unstructured":"Huber JH, Ji M, Shih YH, Wang M, Colditz G, Chang SH (2023) Disentangling age, gender, and racial\/ethnic disparities in multiple myeloma burden: a modeling study. Nat Commun 14(1):5768","journal-title":"Nat Commun"},{"issue":"41","key":"2142_CR26","doi-asserted-by":"publisher","first-page":"e20052","DOI":"10.1200\/JCO.2023.41.16_suppl.e20052","volume":"1","author":"AK Ghosh","year":"2023","unstructured":"Ghosh AK, McGuire N, Ruiz Vega R, Alaws H, Adewunmi C, Abidoye O et al (2023) Identifying associations between race and gender in the incidence and mortality of patients with multiple myeloma. J Clinical Oncol 1(41):e20052\u2013e20052","journal-title":"J Clinical Oncol"},{"issue":"8","key":"2142_CR27","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","volume":"20","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ et al (2011) Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiol Biomark Prev 20(8):1703\u20131707","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"2142_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/ERC-15-0029","volume":"22","author":"R R\u00edos","year":"2015","unstructured":"R\u00edos R, Lupia\u00f1ez CB, Campa D, Martino A, Mart\u00ednez-L\u00f3pez J, Mart\u00ednez-Bueno M et al (2015) Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer 22(4):545\u2013559","journal-title":"Endocr Relat Cancer"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-026-02142-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:59:40Z","timestamp":1773392380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-026-02142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2142"],"URL":"https:\/\/doi.org\/10.1007\/s10552-026-02142-3","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"51"}}